CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023

Dec 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-12-06

Reporting Person: INGENITO GARY (Chief Med. & Reg. Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-06	Common stock, par value $0.001 per share	M	50000	$1.13	Acquired	88367	Direct
2023-12-06	Common stock, par value $0.001 per share	S	50000	$14.02	Disposed	38367	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-06	Options to purchase common stock	$1.13	M	50000	Disposed	2024-01-03	Common Stock (50000)	Direct

Footnotes

F1: Dr. Ingenito sold the shares on the open market for personal reasons and to fund the exercise price and tax withholding of the exercise of the stock option, and not as a result of any disagreement with the Company.

F2: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.89 to $14.165 per share.

F3: Options vested in three annual tranches beginning on January 3, 2018.